Last reviewed · How we verify
GSK1550188 IV
At a glance
| Generic name | GSK1550188 IV |
|---|---|
| Sponsor | GlaxoSmithKline |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's Syndrome (PHASE2)
- A Study of Belimumab in Idiopathic Membranous Glomerulonephropathy (PHASE2)
- Japanese phase1 Study of Belimumab (IV vs SC) (PHASE1)
- Phase I Study of GSK1550188 in Japanese Subjects With Systemic Lupus Erythematosus (SLE) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GSK1550188 IV CI brief — competitive landscape report
- GSK1550188 IV updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI